| Identification | Back Directory | [Name]
L-Phenylalanine, 4-fluoro-N-[(2E)-1-oxo-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]- | [CAS]
2708177-73-3 | [Synonyms]
PI3K/Akt/CREB activator 1
L-Phenylalanine, 4-fluoro-N-[(2E)-1-oxo-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]- | [Molecular Formula]
C19H15F4NO3 | [MOL File]
2708177-73-3.mol | [Molecular Weight]
381.32 |
| Chemical Properties | Back Directory | [Boiling point ]
557.6±50.0 °C(Predicted) | [density ]
1.365±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
3.47±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD)[1]. | [in vivo]
PI3K/Akt/CREB activator 1 (compound AE-18; 5 and 10 mg/kg; i.g.; male Sprague-Dawley rats with chronic cerebral hypoperfusion (CCH) model) improves cerebral blood flow (CBF) recovery after bilateral common carotid artery occlusion (BCCAO)[1].
PI3K/Akt/CREB activator 1 (5 and 10 mg/kg; i.g.; for 5 d) mitigates impairment of learning and memory in chronic cerebral hypoperfusion (CCH) rat model and alleviates CCH-induced pathological injury in the hippocampus after BCCAO[1].
| Animal Model: | Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model[1] | | Dosage: | 5 and 10 mg/kg | | Administration: | Oral gavage; daily, for 6 weeks | | Result: | Promoted the recovery of CBF after BCCAO. |
| Animal Model: | Male Sprague-Dawley rats (200-220 g) with chronic cerebral hypoperfusion (CCH) model[1] | | Dosage: | 5 and 10 mg/kg | | Administration: | Oral gavage; daily, for 5 days | | Result: | Reduced escape latency from day 1 to day 5 of the morris water maze (MWM) test compared with the CCH group.
Improved cognitive deficits in CCH rat model.
|
| [References]
[1] Feng JH, et, al. Protective Effects of 4-Trifluoromethyl-(E)-cinnamoyl]-L-4-F-phenylalanine Acid against Chronic Cerebral Hypoperfusion Injury through Promoting Brain-Derived Neurotrophic Factor-Mediated Neurogenesis. ACS Chem Neurosci. 2022 Oct 16. DOI:10.1021/acschemneuro.2c00417 |
|
|